Akero Therapeutics (AKRO) News Today $29.34 +0.94 (+3.31%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $29,130.00 in StockDecember 19 at 9:05 AM | insidertrades.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 1,000 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 1,000 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $29.13, for a total transaction of $29,130.00. Following the completion of the transaction, the vice president now directly owns 34,258 shares of the company's stock, valued at $997,935.54. This represents a 2.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.December 18 at 10:24 PM | marketbeat.comCatriona Yale Sells 9,074 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 9,074 shares of the business's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $29.11, for a total transaction of $264,144.14. Following the completion of the sale, the insider now directly owns 95,648 shares of the company's stock, valued at approximately $2,784,313.28. The trade was a 8.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.December 18 at 10:23 PM | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Stock Price Down 4.1% - Time to Sell?Akero Therapeutics (NASDAQ:AKRO) Shares Down 4.1% - Here's What HappenedDecember 18 at 1:54 PM | marketbeat.comState Street Corp Lowers Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)State Street Corp trimmed its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,502,946 shares of thDecember 18 at 3:35 AM | marketbeat.comFmr LLC Acquires 26,691 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Fmr LLC boosted its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 732.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,337 shares of the company's stock after acquiring an additiDecember 18 at 3:11 AM | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Shares Up 3.5% - Here's What HappenedAkero Therapeutics (NASDAQ:AKRO) Stock Price Up 3.5% - Here's WhyDecember 17, 2024 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 9.1% in NovemberAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 3,290,000 shares, a decrease of 9.1% from the November 15th total of 3,620,000 shares. Based on an average daily volume of 570,700 shares, the days-to-cover ratio is presently 5.8 days.December 15, 2024 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $28,480.75 in StockDecember 13, 2024 | insidertrades.comWellington Management Group LLP Boosts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Wellington Management Group LLP lifted its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 54.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,896,632 shares of the company's stock afterDecember 9, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Decreases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Charles Schwab Investment Management Inc. cut its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 4.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 532,596 shares of the company'sDecember 8, 2024 | marketbeat.comWhy Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 5, 2024 | msn.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 10,000 SharesDecember 5, 2024 | insidertrades.comRTW Investments LP Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)RTW Investments LP lifted its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 9.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,919,435 shares of the company's stockDecember 5, 2024 | marketbeat.comRedmile Group LLC Sells 226,994 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Redmile Group LLC reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 14.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,387,479 shares of the company's stDecember 5, 2024 | marketbeat.comPoint72 Asset Management L.P. Acquires New Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Point72 Asset Management L.P. acquired a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,303,323 shares of the company's stDecember 5, 2024 | marketbeat.comJanus Henderson Group PLC Increases Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Janus Henderson Group PLC lifted its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 2.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,077,478 shares of the company's stock afterDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Acquires Shares of 65,307 Akero Therapeutics, Inc. (NASDAQ:AKRO)Cinctive Capital Management LP acquired a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 65,307 shares of the company's stock, valued atDecember 4, 2024 | marketbeat.com47,000 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by Erste Asset Management GmbHErste Asset Management GmbH acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 47,000 shares of the company's stock, valued at approximately $1,3December 4, 2024 | marketbeat.comIntech Investment Management LLC Acquires Shares of 17,107 Akero Therapeutics, Inc. (NASDAQ:AKRO)Intech Investment Management LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 17,107 shares of the company's stock, valued at apprDecember 2, 2024 | marketbeat.comFred Alger Management LLC Boosts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Fred Alger Management LLC lifted its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 117.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 269,601 shares of the company's stock after purchasing an additional 145,813 sharDecember 1, 2024 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of "Moderate Buy" by AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have given a buyDecember 1, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Reduces Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Connor Clark & Lunn Investment Management Ltd. lessened its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 85.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,159 shares of the company's stock afterDecember 1, 2024 | marketbeat.comAkero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNovember 26, 2024 | markets.businessinsider.comAkero Therapeutics, Inc. (NASDAQ:AKRO) is Propel Bio Management LLC's 6th Largest PositionPropel Bio Management LLC grew its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 4.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 343,729 shares of the company's stock after bNovember 26, 2024 | marketbeat.comAkero Therapeutics Receives Buy Rating for Promising Efruxifermin Developments in MASH TreatmentNovember 23, 2024 | markets.businessinsider.comCatriona Yale Sells 9,061 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockNovember 20, 2024 | insidertrades.comAkero Therapeutics initiated with a Buy at CitiNovember 19, 2024 | markets.businessinsider.comAkero Therapeutics (AKRO) Receives a Buy from Phillip SecuritiesNovember 19, 2024 | markets.businessinsider.comCitigroup Initiates Coverage of Akero Therapeutics (AKRO) with Buy RecommendationNovember 19, 2024 | msn.comHC Wainwright Reaffirms "Buy" Rating for Akero Therapeutics (NASDAQ:AKRO)HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Akero Therapeutics in a research report on Monday.November 18, 2024 | marketbeat.comCitigroup Begins Coverage on Akero Therapeutics (NASDAQ:AKRO)Citigroup assumed coverage on shares of Akero Therapeutics in a research report on Monday. They issued a "buy" rating and a $65.00 price objective for the company.November 18, 2024 | marketbeat.comPromising Clinical Trial Results and Future Potential Justify Buy Rating for Akero TherapeuticsNovember 17, 2024 | markets.businessinsider.comAkero to showcase new analyses of Phase 2b HARMONY study at AASLDNovember 15, 2024 | markets.businessinsider.comAkero Therapeutics (NASDAQ:AKRO) Shares Down 6.4% - What's Next?Akero Therapeutics (NASDAQ:AKRO) Stock Price Down 6.4% - Here's WhyNovember 15, 2024 | marketbeat.comSimplify Asset Management Inc. Boosts Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)Simplify Asset Management Inc. increased its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 15.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 283,766 shares of the company's stock after acquiring an aNovember 15, 2024 | marketbeat.comAkero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024November 15, 2024 | globenewswire.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 19.1% in OctoberAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) saw a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 3,820,000 shares, a decrease of 19.1% from the October 15th total of 4,720,000 shares. Based on an average trading volume of 512,300 shares, the days-to-cover ratio is presently 7.5 days.November 15, 2024 | marketbeat.comHC Wainwright Has Negative Outlook of AKRO FY2024 EarningsAkero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Equities research analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Akero Therapeutics in a report released on Monday, November 11th. HC Wainwright analyst E. Arce now anticipates that the company will earnNovember 14, 2024 | marketbeat.comAkero Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 13, 2024 | globenewswire.comHC Wainwright Has Strong Estimate for AKRO FY2028 EarningsAkero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Research analysts at HC Wainwright raised their FY2028 earnings per share estimates for Akero Therapeutics in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst E. Arce now expects that the compaNovember 13, 2024 | marketbeat.comAkero Therapeutics price target raised to $35 from $30 at BofANovember 13, 2024 | markets.businessinsider.comBank of America Securities Reaffirms Their Hold Rating on Akero Therapeutics (AKRO)November 13, 2024 | markets.businessinsider.comAkero Therapeutics: Promising Pipeline and Strong Financial Position Suggest Favorable Risk/Reward ProfileNovember 10, 2024 | markets.businessinsider.comAkero Therapeutics (NASDAQ:AKRO) Releases Quarterly Earnings Results, Misses Expectations By $0.17 EPSAkero Therapeutics (NASDAQ:AKRO - Get Free Report) released its quarterly earnings data on Friday. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17).November 9, 2024 | marketbeat.comAkero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 9, 2024 | finance.yahoo.comBuy Rating Reaffirmed for Akero Therapeutics: Strong Financials and Promising Clinical Trials Bolster ConfidenceNovember 9, 2024 | markets.businessinsider.comAkero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | globenewswire.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 50,716 SharesNovember 6, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of "Moderate Buy" from AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy ratinNovember 6, 2024 | marketbeat.com Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼0.750.60▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼107▲AKRO Articles Average Week Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News Lantheus News Legend Biotech News Nuvalent News Blueprint Medicines News Elanco Animal Health News Cytokinetics News TG Therapeutics News Viking Therapeutics News BridgeBio Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKRO Stock Alerts